Lyka Labs Limited

£



STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST MARCH, 2016

	Particulars	Particulars Quarter Ended		Year to date figure for Current period Ended	Rs. In Lakhs Previous yea Ended	
		31-Mar-2016	31-Dec-2015	31-Mar-2015	31-Mar-2016	30-Jun-2015
					9 months	12 months
1. 		(Audited)	(Unaudited)	(Unaudited)	(Audited)	
1	Income from operations			(encounce)	(Audited)	(Audited)
	(a) Net Sales/Income from operations (Net of excise duty)	1,745.91	1,748.68	1,794.04	5,447.02	8,307.33
	(b) Other Operating Income	100.00				
	Product and the second	109.06	64.62	95.50	279.94	741.10
	Total income from operations (net)	1,854.97	1,813.30	1,889.54	5,726.96	9,048.43
2	Expenses					
	(a) Cost of Materials Consumed	736.31	739.97	1 407 37	2.245.45	100 <u>44-044</u> 0005-0
	(b) Purchase of traded goods	390.31	285.39	1,407.27 106.21	2,345.49	4,658.11
	(c) Change in inventories of finished goods,	57.73	62.39	(450.19)	908.25 167.57	479.22
	work-in-progress and stock-in-trade,		52.55	(+50.19)	107.57	(56.98)
	(d) Employee benefits expense	226.32	214.89	242.63	658.11	963.58
	(e) Depreciation and amortisation expense	87.30	88.44	31.01	264.02	383.26
	(f) Other expenses	274.89	301.48	204.53	853.79	1,171.44
	Total expenses	1,772.86	1,692.56	1,541.46	5,197.23	7,598.63
3	Profit/(Loss) from Operations before Other Income,Finance cost and Exceptional items (1-2)	82.11	120.74	348.08	529.73	1,449.80
4	Other Income	202.67				
5	Profit/(Loss) from ordinary activities before finance	293.67	234.05	38.54	1,124.11	170.73
	cost and exceptional Items (3+4)	375.78	354.79	386.62	1,653.84	1,620.53
6	Finance costs	377.28	344.09	421.98	1 144 25	1 02 4 72
7	Profit/(Loss) from ordinary activities after finance		544.05	421.50	1,144.35	1,834.72
	cost but before exceptional Items (5-6)	(1.50)	10.70	(35.36)	509.49	(214.19)
8	Exceptional Items (Net)	(84.92)	-	-	(60.23)	(363.47)
9	Prior Period Adjustments	(35.78)	(33.49)	2	87.70	12.60
0	Profit/(Loss) from Ordinary Activities	119.20	44.19	(25.20)		
	before tax (7-8-9)	115.20	44.13	(35.36)	482.02	136.68
1	Tax Expenses	38	2	-	5	-
2	Net Profit/(Loss) from Ordinary activities after tax (10-11)	119.20	44.19	(35.36)	482.02	136.68
3	Extraordinary Item (net of tax expenses)				1.0	
4	Net Profit/(Loss) for the period (12+13)	119.20	44.19	(35.36)	482.02	136.68
5	Paid up equity share capital	2,204.00	2,204.00	2,158.00		
1	(face value Rs.10/- per share)	2,204.00	2,204.00	2,158.00	2,204.00	2,158.00
ā.	Reserve excluding Revaluation Reserve as					
-	per balance sheet of previous accounting year	-			1075.01	3.511.10
L	Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised)				4,076.01	3,511.18
	(a) Basic	0.53	0.19	(0.18)	2.17	0.58
L	(b) Diluted	0.53	0.19	(0.18)	2.17	0.58
	Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised) (a) Basic					0.00
	(a) Basic (b) Diluted	0.53	0.19	(0.18)	2.17	0.58
-	lo/ onated	0.53	0.19	(0.18)	2.17	0.58



Notes:

- 1. The above Audited Financial results has been reviewed by the Audit Committee and approved and taken on record by the Board of Directors of the Company at their meeting held on 27th May, 2016.
- 2. The figures for the last quarter ended 31st March, 2016 being balancing figures between audited figures in respect of the period ended 31st March, 2016 and published year to date figures upto 31st December, 2015.
- The Statutory Auditors of the Company have carried out the audit on Standalone basis of the financial results for the quarter ended 31st March, 2016 and for the period ended 31st March, 2016
- 4. During the Quarter the Company has charged to Profit & Loss Account Rs.21.18 lacs being depreciation on revalued assets.
- 5. Exceptional items consist of:
 - During the period Company has written back liabilities and excess provisions which are no longer required of Rs.87.96 lacs.
- 6. Current year Tax has not been provided in view of unabsorbed business losses and depreciation of the earlier years.
- 7. The Company has one Single Segment "Pharmaceuticals".
- 8. The figures for the Current Period ended 31st March, 2016 being for a period of 9 months are not comparable with those of the Previous Year for 12 months.
- 9. Figures for previous year have been regrouped/rearranged wherever necessary, to conform to the relevant current period classification.

For LYKA LABS LIMITED Manh

N. I. GANDHI (DIN: 00021530) Chairman & Managing Director

Mumbai 27-May-16

Lyka Labs Limited



_	Particulars	As at 31st March, 2016	As at 30th June 2015
A		Audited	Audited
1	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share Capital	2,312.57	2,266.53
	(b) Reserves and Surplus	4,337.73	3,817.72
	Sub-Total -Shareholders' Fund	6,650.30	6,084.29
2	Money received against Share Warrants		
		•	32.20
3			
	(a) Long-Term Borrowings	2,526.99	2,873.48
	(b) Other Long-Term Liabilities	13.95	48.95
	(c) Long-Term Provisions	207.11	304.59
4	Sub -Total -Non -Current liabilities	2,748.05	3,227.02
•			
	(a) Short-Term Borrowings	4,624.26	3,607.29
	(b) Trade Payables (c) Other Current Liabilities	3,236.90	3,940.67
	(d) Short-Term Provisions	5,453.00	6,375.21
		90.22	45.09
	Sub -Total -Current liabilities	13,404.38	13,968.26
	TOTAL-EQUITY AND LIABILITIES	22,802.73	23,311.77
i.	ASSETS Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible Assets	5,597.57	F 777 77
	(ii) Capital Work-in-Progress	1,736.28	5,737.23
	(iii) Intangible Assets	428.18	1,606.41 429.60
		420.10	429.00
	(iii) Intangible assets under development	1 280 66	
		1,280.66	1,096.43
	(b) Non-Current Investments	9,042.69	1,096.43 8,869.67
		9,042.69 6,256.56	1,096.43 8,869.67 6,256.56
	(b) Non-Current Investments (c) Long-Term Loans and Advances Sub -Total -Non-Current assets	9,042.69	1,096.43 8,869.67 6,256.56 1,801.77
	(b) Non-Current Investments (c) Long-Term Loans and Advances Sub -Total -Non-Current assets Current Assets	9,042.69 6,256.56 1,630.33	1,096.43 8,869.67 6,256.56
	(b) Non-Current Investments (c) Long-Term Loans and Advances Sub -Total -Non-Current assets (a) Inventories	9,042.69 6,256.56 1,630.33	1,096.43 8,869.67 6,256.56 1,801.77
	(b) Non-Current Investments (c) Long-Term Loans and Advances Sub -Total -Non-Current assets (a) Inventories (b) Trade Receivables	9,042.69 6,256.56 1,630.33 16,929.58	1,096.43 8,869.67 6,256.56 1,801.77 16,928.00
	(b) Non-Current Investments (c) Long-Term Loans and Advances Sub -Total -Non-Current assets (a) Inventories (b) Trade Receivables (c) Cash and Cash Equivalents	9,042.69 6,256.56 1,630.33 16,929.58 696.42	1,096.43 8,869.67 6,256.56 1,801.77 16,928.00 1,255.83
	(b) Non-Current Investments (c) Long-Term Loans and Advances Sub -Total -Non-Current assets (a) Inventories (b) Trade Receivables (c) Cash and Cash Equivalents (d) Short-Term Loans and Advances	9,042.69 6,256.56 1,630.33 16,929.58 696.42 2,644.85	1,096.43 8,869.67 6,256.56 1,801.77 16,928.00 1,255.83 2,883.27
	(b) Non-Current Investments (c) Long-Term Loans and Advances Sub -Total -Non-Current assets (a) Inventories (b) Trade Receivables (c) Cash and Cash Equivalents (d) Short-Term Loans and Advances (e) Other Current Assets	9,042.69 6,256.56 1,630.33 16,929.58 696.42 2,644.85 173.41 2,218.96 139.51	1,096.43 8,869.67 6,256.56 1,801.77 16,928.00 1,255.83 2,883.27 170.35
	(b) Non-Current Investments (c) Long-Term Loans and Advances Sub -Total -Non-Current assets (a) Inventories (b) Trade Receivables (c) Cash and Cash Equivalents (d) Short-Term Loans and Advances	9,042.69 6,256.56 1,630.33 16,929.58 696.42 2,644.85 173.41 2,218.96	1,096.43 8,869.67 6,256.56 1,801.77 16,928.00 1,255.83 2,883.27 170.35 1,934.81

N.I.Gandhi (DIN : 00021530) (Chairman & Managing Director)

Lyka Labs Limited



1	Particulars		Quert			(R.s.in Lakhs)
			Quarter Ended		Year to date figure for the current period ended	Year to date figure for the previous year ended
		31-03-2016	31-12-2015	31-03-2015	31-03-2016 9 Months	30-06-2015 12 Months
		(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	 Income from operations (a) Net Sales/Income from operations (Net of excise duty) 	3273.42	2963.35	3905.58	12,543.88	15,705.1
	(b) Other Operating Income	188.34	109.66	147.41	522.47	921.4
	Total income from operations (net)	3461.76	3073.01	4052.99	13,066.35	16,626.5
2	Expenses				13,000.33	10,020.5
	(a) Cost of Materials Consumed	943.70	739.97	1407.27	2,345.49	4,658.1
	(b) Purchase of traded goods	912.84	1015.98	1351.39	4,444.82	4,417.0
	 (c) Change in inventories of finished goods, work-in-progress and stock-in-trade, 	90.21	(9.94)	(494.56)	252.51	(2.47
	(d) Employee benefits expense	402.70	375.40	415.27	1,471.19	1,726.3
	(e) Depreciation and amortisation expense	249.78	253.71	216.53	932.46	1,087.3
	(f) Other expenses	709.80	628.39	847.91	2,476.93	3,091.0
	Total expenses	3309.03	3003.51	3743.81	11,923.40	14,977.3
3	Profit/(Loss) from Operations before Other Income,Finance cost and Exceptional items (1-2)	152.73	69.50	309.18	1,142.95	1,649.2
4	Other Income	10.36	81.93	54.06	151.54	235.2
5	Profit/(Loss) from ordinary activities before finance cost and exceptional Items (3+4)	163.09	151.43	363.25	1,294.49	1,884.50
	Finance costs	450.89	458.31	526.34	1,518.84	2,415.92
	Profit/(Loss) from ordinary activities after finance costs but before exceptional Items (5-6)	(287.80)	(306.88)	(163.09)	(224.35)	(531.42)
	Exceptional Items (Net)	(1,138.57)	(0.08)		738.18	(178.27)
	Prior Period Items		47.54		(123.47)	12.60
	Profit/(Loss) from Ordinary Activities before tax (7+8+9)	(1,426.37)	(259.42)	(163.09)	390.36	(365.75)
	Tax Expenses	251.53	273.81	6.15	18.63	106.40
	Net Profit/(Loss) from Ordinary activities after tax (10-11)	(1,677.90)	14.39	(169.23)	408.99	(472.15)
	Extraordinary Item (net of tax expenses)	-		•	(a)	2
	Net Profit/(Loss) for the period	(1,677.90)	14.39	(169.23)	408.99	(472.15)
	Share of Profit/(Loss) of associates		2			
	Mmontly Interest	(478.43)	39.23	27.21	40.30	(22.77)
	Net Profit/ (Loss) after taxes, minority interest and	Co.	1103408	1000	.5.50	(22.17)

Lyka Labs Limited



L		LYKA LABS LIMI				theare through Inn
	STATEMENT OF CONSOLIDATED AUDITED FINANCI	AL RESULTS FOR	THE QUARTER	AND PERIOD EI	NDED 31ST MARC	H, 20 16
⊢	P-rivel.					(Rs.in Lakhs)
	, Particulars	Quarter Ended			Year to date figure for the current period ended	Ye ar to date figure for the previous year ended
		31-03-2016	31-12-2015	31-03-2015	31-03-2016 9 Months	30-06-2015 12 Months
-		(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
18	Paid up equity share capital (face value Rs.10/- per share)	2204.00	2204.00	2,158.00	2,204.00	2,158.00
19	Reserve excluding Revaluation Reserve as per Balance Sheet of previous accounting year				1,527.19	1,077.81
20	i Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised)					
- 1	(a) Basic	(5.45)	0.23	(0.91)	1.65	(2.34
21	 (b) Diluted ii Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised) 	(5.45)	0.23	(0.91)	1.65	(2.34
1	(a) Basic	(5.45)	0.23	(0.91)	1.65	(2.34
	(b) Diluted	(5.45)	0.23	(0.91)	1.65	(2.34)

2ª



Notes:

- 1. The above Audited Financial results has been reviewed by the Audit Committee and approved and taken on record by the Board of Directors of the Company at their meeting held on 27th May, 2016.
- 2. The figures for the last quarter ended 31st March, 2016 being balancing figures between audited figures in respect of the period ended 31st March, 2016 and published year to date figures upto 31st December, 2015.
- 3. The Statutory Auditors of the Company have carried out the audit on Consolidated basis of the financial results for the period ended 31st March, 2016.
- Audited financial results for the period ended 31st March, 2016 have been consolidated with that of Lyka BDR International Ltd., Lyka Healthcare Ltd., and Lyka Exports Ltd., for the year ended 31st March, 2016
- 5. During the Quarter the Company has charged to Profit & Loss Account Rs.21.18 lacs being depreciation on revalued assets.
- 6. Exceptional items consist of :

Sr.	Particulars	Quarter Ended	Period ended
No.		31st March 2016	31st March, 2016
		(Rs. In lacs)	(Rs. In lacs)
a)	Loss/(Gain) on sale of Animal Health Care Limited	627.64	(1,349.11)
b)	Irrecoverable Claim/Advance written off	0.55	0.55
c)	Excess Provision no longer required written back	(20.25)	(89.96)
d)	Loss on sale of Fixed Assets (Net)	3.04	3.24
e)	Bad Debts	527.59	697.10
	TOTAL	1,138.57	(738.18)

- 7. Tax expenses comprises of current tax/deferred tax assets.
- 8. The Company has one Single Segment "Pharmaceuticals".
- 9. The figures for the Current Period ended 31st March, 2016 being for a period of 9 months are not comparable with those of the Previous Year for 12 months.
- 10. Figures for previous year have been regrouped/rearranged wherever necessary, to conform to the relevant current period classification.

For LYKA LABS LIMITED

N. I. GANDHI (DIN: 00021530) Chairman & Managing Director

Mumbai 27-May-16



_	Particulars	As at 31st March, 2016	As at 30th June 2015
		Audited	Audited
Α	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
922	(a) Share Capital	7242040 cm	
	(b) Reserves and Surplus	2,312.57	2,266.
	Sub-Total -Shareholders' Fund	2,209.38	2,007.
		4,521.95	4,273.
2	Money received against share warrants		32.3
3	Minority Interest	393.41	351.0
4	Non-Current Liabilities		
	(a) Long-Term Borrowings (b) Other Long-Term Liabilities	2,531.45	2,892.1
	(c) Deffered Tax Liability	139.95	199.4
	(d) Long-Term Provisions	1911	173.7
	Sub -Total -Non -Current liabilities	501.30	495.0
5	Current Liabilities	3,172.70	3,760.4
	(a) Short-Term Borrowings		100000000000000000000000000000000000000
	(b) Trade Payables	5,994.81	5,985.1
	(c) Other Current Liabilities	4,420.95	5,463.5
	(d) Short-Term Provisions	5,441.94	7,940.6
	Sub -Total -Current liabilities	216.19 16,073.89	69.4 19,458.8
	TOTAL-EQUITY AND LIABILITIES	24,161.96	27,876.3
в	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible Assets	5,665.91	5,831.78
	(ii) Capital Work-in-Progress	1,736.28	1,606.4
	(iii) Intangible Assets (iv) Intangible assets under development	4,756.82	6,332.08
	(iv) intaligible assets under development	1,280.66	1,096.43
	(b) Non-Current Investments	13,439.67	14,866.70
	(c) Deferred Tax Asset	38.65	31.60
	(c) Long-Term Loans and Advances	111.24	
	Sub -Total -Non-Current assets	2,391.57	2,809.32
0	Current Assets	15,981.13	17,707.62
	(a) Inventories	1,081.16	1,924.57
- 1	(b) Trade Receivables	4,329.49	5,670.14
	(c) Cash and Cash Equivalents	555.52	651.30
		1,969.56	1,660.46
	(d) Short-Term Loans and Advances		
	(d) Short-Term Loans and Advances (e) Other Current Assets	245.10	262.26
	(d) Short-Term Loans and Advances (e) Other Current Assets Sub -Total -Current assets	245.10 8,180.83	262.26 10,168.73

LYKA LABS LIMITED Consolidated Statement of Assets and Liabilities